A bold federal experiment is about to force digital health companies to prove their tools actually work or risk losing half their pay.

For years, digital health startups sold the promise of continuous care without facing the strict financial accountability of traditional medicine. That free pass ends on July 5, 2026. The CMS Innovation Center is launching its 10-year ACCESS model, forcing a shift from tech hype to clinical proof.

Under this new initiative, more than 150 healthcare organizations will test digital tools for managing hypertension, diabetes, chronic pain, and depression. The stakes are high. The payment structure is a 50/50 split, meaning half of a provider’s reimbursement depends entirely on patients meeting specific clinical goals.

The Compliance Trap

This is not just a new billing code. It is a fundamental shift in how digital health businesses must operate. Many of the participating startups have never navigated the complex world of Medicare.

They now face a dual challenge. They must meet strict federal interoperability standards while managing the financial risk of patient behavior. If a patient stops logging their blood sugar, the startup loses money.

Furthermore, the FDA is running a parallel TEMPO pilot to streamline how these tools integrate. This shows a coordinated federal push to normalize digital therapeutics.

Why This Matters

This model signals the end of the venture-backed “user growth” era in digital health. Survival now requires hard clinical data and robust regulatory compliance.

If successful, it will redefine how public insurance funds software. If it fails under the weight of administrative hurdles, it could freeze digital health integration for a decade.